Status and phase
Conditions
Treatments
About
Clinical Trial for the safety and efficacy of BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
Full description
In this study, 100 patients with relapsed refractory multiple myeloma were proposed to undergo BCMA CAR-T cell therapy. Under the premise that its safety has been clarified in previous studies, further observation and evaluation of the effectiveness of BCMA CAR-T cell therapy for relapsed refractory multiple myeloma; At the same time, on the basis of expanding the sample size, more safety data on BCMA CAR-T cell treatment for relapsed refractory multiple myeloma were accumulated, including rare and delayed complications.
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Histologically confirmed diagnosis of multiple myeloma (MM):
Patients with BCMA positive relapsed/refractory MM;
Relapsed after hematopoietic stem cell transplantation;
Cases with recurrent positive minimal residual disease;
Repeated MRD(+) refractory resistant cases
Extramedullary leision which is hard to be eradicated by chemotherapy or radiotherapy.
Exclusion Criteria:
Subjects with any of the following exclusion criteria were not eligible for this trial:
Primary purpose
Allocation
Interventional model
Masking
100 participants in 1 patient group
Loading...
Central trial contact
Yongxian Hu, PhD; He Huang, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal